{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:44:16Z","timestamp":1790390656578,"version":"4.1.0"},"reference-count":30,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the pharmacology, efficacy, and safety of ferric maltol (FM), an oral iron formulation, for iron deficiency anemia (IDA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A MEDLINE\/PubMed and EMBASE (January 1, 1985, to June 19, 2020) literature search was performed using the terms ferric maltol, accrufer, feraccru, iron maltol, ferric trimaltol, iron deficiency, iron deficiency anemia, inflammatory bowel disease, and chronic kidney disease. Additional data sources included prescribing information, abstracts, and the National Institutes of Health Clinical Trials Registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection\/Data Extraction:<\/jats:title>\n                    <jats:p>English language literature evaluating FM pharmacology, pharmacokinetics, efficacy, or safety in the treatment of IDA were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>FM is a ferric, non\u2013salt-based oral iron formulation demonstrating improved tolerance in patients with previous intolerance to other iron formulations. Phase 3 trials demonstrated significant improvements in anemia and serum iron parameters in patients with inflammatory bowel disease (IBD) and chronic kidney disease (CKD). Common adverse effects were gastrointestinal intolerance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>FM is an effective and well-tolerated alternative to oral iron salts for patients with IBD or CKD and IDA. Emerging data suggest that FM is noninferior to intravenous (IV) ferric carboxymaltose in patients with IBD and IDA. Prior to selecting FM over IV iron products, consideration should be given to time to normalization of Hb, ease of administration, cost, and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>FM is a relatively safe, effective oral iron therapy that may be better tolerated than other oral iron formulations. FM may be an effective alternative to IV iron in patients with IBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020941014","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T10:04:24Z","timestamp":1594116264000},"page":"222-229","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":26,"title":["Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6764-5263","authenticated-orcid":false,"given":"Adonice","family":"Khoury","sequence":"first","affiliation":[{"name":"University of Florida College of Pharmacy, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaley A.","family":"Pagan","sequence":"additional","affiliation":[{"name":"University of Florida College of Pharmacy, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Z.","family":"Farland","sequence":"additional","affiliation":[{"name":"University of Florida College of Pharmacy, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"key":"bibr1-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.06.028"},{"key":"bibr2-1060028020941014","first-page":"627","volume-title":"Williams Hematology","author":"Ganz T","year":"2016","edition":"9"},{"key":"bibr3-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1401038"},{"key":"bibr4-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)83687-1"},{"key":"bibr5-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1097\/mib.0000000000000314"},{"key":"bibr6-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13665"},{"key":"bibr7-1060028020941014","first-page":"617","volume-title":"Williams Hematology","author":"Ganz T","year":"2016","edition":"9"},{"key":"bibr8-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314472.512"},{"key":"bibr9-1060028020941014","unstructured":"Accrufer. Package insert. Shield Therapeutics; 2019."},{"key":"bibr10-1060028020941014","unstructured":"European Medicine Agency. Feraccru. Accessed January 31, 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/feraccru#product-information-section"},{"key":"bibr11-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0b013e32831ef1cd"},{"key":"bibr12-1060028020941014","first-page":"98","volume":"87","author":"Short MW","year":"2013","journal-title":"Am Fam Physician"},{"key":"bibr13-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2019.05.002"},{"key":"bibr14-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1991.tb12240.x"},{"key":"bibr15-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1987.tb06249.x"},{"key":"bibr16-1060028020941014","unstructured":"National Center for Biotechnology Information. Ferric maltol. Accessed March 23, 2020. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Ferric-maltol"},{"key":"bibr17-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1990.tb05407.x"},{"key":"bibr18-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00380.x"},{"key":"bibr19-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1096929"},{"key":"bibr20-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-016-0334-5"},{"key":"bibr21-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jju027.639"},{"key":"bibr22-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.761599"},{"key":"bibr23-1060028020941014","volume-title":"Lexi-Drugs","author":"Lexicomp Online","year":"2020"},{"key":"bibr24-1060028020941014","first-page":"70","volume":"29","author":"Kopyt N.","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"bibr25-1060028020941014","first-page":"7","author":"Howaldt S.","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"bibr26-1060028020941014","unstructured":"Shield Therapeutics PLC. AEGIS-H2H study update [press release]. Published March 17, 2020. Accessed June 1, 2020. https:\/\/www.shieldtherapeutics.com\/rns_news\/aegis-h2h-study-update\/"},{"key":"bibr27-1060028020941014","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz203.695"},{"key":"bibr28-1060028020941014","volume-title":"Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity: Vitamin and Mineral Nutrition Information System (WHO\/NMH\/NHD\/MNM\/111)","author":"World Health Organization","year":"2011"},{"key":"bibr29-1060028020941014","unstructured":"Safety and efficacy study of oral ferric maltol compared to intravenous iron to treat iron deficiency anaemia in IBD. ClinicalTrials.gov identifier: NCT02680756. Updated April 22, 2020. Accessed March 27, 2020. https:\/\/ClinicalTrials.gov\/show\/NCT02680756"},{"key":"bibr30-1060028020941014","unstructured":"Center for Drug Evaluation and Research. Multi-disciplinary review and evaluation NDA 212320, ferric maltol, Accrufer. Accessed May 30, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212320Orig1s000MultidisciplineR.pdf"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020941014","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020941014","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020941014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:42Z","timestamp":1777374942000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020941014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1177\/1060028020941014"],"URL":"https:\/\/doi.org\/10.1177\/1060028020941014","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]}}}